Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
24 Mar 2017
Change (% chg)

$-0.17 (-9.09%)
Prev Close
$1.92
Open
$1.95
Day's High
$1.95
Day's Low
$1.75
Volume
197,775
Avg. Vol
84,731
52-wk High
$4.00
52-wk Low
$1.55

Latest Key Developments (Source: Significant Developments)

Biodelivery Sciences secures debt financing with CRG
Thursday, 23 Feb 2017 07:30am EST 

Biodelivery Sciences International Inc : Biodelivery Sciences secures debt financing with CRG . Biodelivery Sciences International - entered into a senior credit facility with affiliates of CRG LP to retire existing credit facility .Says new credit facility consists of $45 million to be drawn at closing.  Full Article

Stonepine Capital Management reports a 6 pct passive stake in Biodelivery Sciences International as of Jan 3, 2017
Friday, 13 Jan 2017 03:39pm EST 

Stonepine Capital Management LLC:Stonepine Capital Management LLC reports a 6 percent passive stake in Biodelivery Sciences International Inc as of Jan 3, 2017 - SEC filing.  Full Article

BioDelivery Sciences International closed on deals contemplated by termination agreement
Monday, 9 Jan 2017 04:42pm EST 

Biodelivery Sciences International Inc :Biodelivery sciences international-closed on deals contemplated by termination agreement, dated dec. 7, 2016 by and between co, its units - sec filing.  Full Article

BioDelivery Sciences reacquires license to BELBUCA from Endo Pharmaceuticals
Thursday, 8 Dec 2016 06:00am EST 

BioDelivery Sciences International Inc - : BioDelivery Sciences reacquires license to BELBUCA™ from Endo Pharmaceuticals . Endo will not be obligated to any future milestone payments to BDSI . Return of BELBUCA is expected to be accretive by improving BDSI's net income and earnings per share in 2017 . BDSI will also explore other options for longer-term growth for BELBUCA both within and ex-U.S . As a result of agreement, world-wide rights to BELBUCA will be transferred back to BDSI . Agreement goes into effect on January 6, 2017. . Specific financial terms of agreement have not been disclosed . Financial terms do not have a material impact on company's going forward cash runway . Total cost of transaction to BDSI will not materially impact BDSI's cash flow going forward .BDSI will not be responsible for future royalties or milestone payments to Endo.  Full Article

Biodelivery Sciences Q2 loss per share $0.31
Tuesday, 9 Aug 2016 06:00am EDT 

Biodelivery Sciences International Inc : Q2 loss per share $0.31 . Q2 revenue view $3.4 million -- Thomson Reuters I/B/E/S . Biodelivery Sciences provides corporate update and reports second quarter 2016 financial results . Q2 revenue rose 189 percent to $5.0 million .Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

BioDelivery Sciences, Collegium Pharma sign licensing deal for pain drug
Wednesday, 11 May 2016 04:19pm EDT 

Collegium Pharmaceutical Inc : Collegium pharmaceutical inc says collegium will be responsible for manufacturing, distribution, marketing and sales of onsolis in u.s. . Financial terms of agreement include $2.5 million upfront non-refundable payment, payable to bdsi within 30 days . Financial terms of agreement include up to $17 million in potential payments based on achievement of milestones . Collegium will be responsible for manufacturing, distribution, marketing and sales of onsolis in u.s . Financial terms of agreement include upper-teen percent royalties based on various annual u.s. Net sales thresholds .Biodelivery sciences and collegium pharmaceutical announce the signing of a licensing agreement for onsolis® in the u.s..  Full Article

Biodelivery Sciences posts Q1 loss of $0.36/share
Tuesday, 10 May 2016 07:28am EDT 

Biodelivery Sciences International Inc : Biodelivery Sciences provides corporate update and reports first quarter 2016 financial results . Q1 loss per share $0.36 . Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S . Q1 revenue $3.0 million versus I/B/E/S view $3 million . IND filing of Buprenorphine 30 day injection for treatment of Opioid dependence and chronic pain anticipated in q3 2016 . Strategic initiatives implemented to better align BUNAVAIL expenses with revenue . Strategic initiatives implemented expected to result in savings of approximately $20 million through 2017 .Says initiatives extend cash runway to Q3 of 2017.  Full Article

BioDelivery Sciences International Inc announces FDA approval of change in BUNAVAIL product specification allowing for immediate release of product
Thursday, 15 Oct 2015 07:30am EDT 

BioDelivery Sciences International Inc:Says FDA has approved company's supplemental new drug application for a manufacturing specification change for BUNAVAIL buccal film.Says new supply of bunavail expected to be in pharmacies within 48 hours.Says approval allows for the immediate release of bunavail inventory to wholesalers.Says will be shipping product to wholesalers wednesday morning; should make product available in pharmacies by friday.  Full Article

BioDelivery Sciences International Inc announces FDA approval of Onsolis
Thursday, 13 Aug 2015 07:00am EDT 

BioDelivery Sciences International Inc:Says FDA approval of new formulation of onsolis (fentanyl buccal soluble film) CII.Says approval of new formulation expected to allow onsolis to return to U.S. market in 2016.Says meda retains the rights to onsolis outside the U.S., where it is marketed in the E.U. as breakyl.Says onsolis is separately licensed by BDSI in Taiwan and South Korea.  Full Article

BioDelivery Sciences International adds $20 million in debt financing from MidCap Financial
Monday, 1 Jun 2015 07:00am EDT 

BioDelivery Sciences International:secured an additional $20.7 million in gross debt funding from midcap financial.Amended and restated facility lowers overall cost of co's debt with midcap through reduction in loan-related fees.Says non-dilutive proceeds from financing to further support the ongoing launch of bunavail.  Full Article

More From Around the Web

BRIEF-BioDelivery Sciences Q4 loss per share $0.29

* Biodelivery sciences provides corporate update and reports fourth quarter and full-year 2016 financial results